8-K: ProKidney Reports Statistically Significant Phase 2 Results for Rilparencel in Chronic Kidney Disease with Diabetes, Bolstering Phase 3 Confidence

ProKidney Corp. announced positive topline results from its Phase 2 REGEN-007 trial, demonstrating statistically significant and clinically meaningful improvement in kidney function for patients with chronic kidney disease and diabetes, and confirmed an upcoming FDA meeting to advance its accelerated approval pathway.

Summary

• ProKidney Corp. reported positive topline results from the Phase 2 REGEN-007 trial evaluating rilparencel in patients with type 1 or 2 diabetes and chronic kidney disease (CKD).
• In Group 1 (n=24), which replicated the Phase 3 PROACT 1 dosing schedule (two rilparencel injections), kidney function stabilized, with the annual decline in eGFR slope improving by 78% from -5.8 mL/min/1.73m2 in the pre-injection period to -1.3 mL/min/1.73m2 post-injection.
• This 4.6 mL/min/1.73m2 per year difference in Group 1 was statistically significant (p<0.001) and clinically meaningful.
• In Group 2 (n=25), which tested an exploratory dosing regimen (single injection with re-dosing trigger), the annual decline in eGFR slope improved by 50% from -3.4 mL/min/1.73m2 to -1.7 mL/min/1.73m2, a 1.7 mL/min/1.73m2 per year difference, which was not statistically significant (p=0.085) but suggested evidence of a dose response.
• No rilparencel-related serious adverse events were observed across all 49 patients who received at least one injection, and the safety profile was consistent with previously reported study results and comparable to a kidney biopsy.
• Full results from REGEN-007 will be submitted to the American Society of Nephrology (ASN) 2025 Kidney Week as a late-breaking clinical trial.
• An FDA Type B meeting is set for summer 2025 to confirm ProKidney's approach to using eGFR slope as the surrogate endpoint in the ongoing Phase 3 PROACT 1 study for accelerated approval.
• ProKidney's current cash, cash equivalents, and marketable securities of $328 million as of March 31, 2025, are expected to fund operations into mid-2027.
• Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food & Drug Administration (FDA).

Sentiment

Score: 9

Explanation: The topline results for REGEN-007 Group 1 are highly positive, showing statistically significant and clinically meaningful stabilization of kidney function, which is a strong indicator for the ongoing Phase 3 trial. The favorable safety profile, coupled with the FDA's confirmation of an accelerated approval pathway using eGFR slope, significantly de-risks the regulatory path. The company's cash runway into mid-2027 also provides financial stability. While Group 2's results were not statistically significant, they still suggested a dose response. Overall, the news is overwhelmingly positive for the company's lead product candidate.

Positives

• Statistically significant and clinically meaningful improvement in annual eGFR slope observed in REGEN-007 Group 1 (78% improvement, 4.6 mL/min/1.73m2 per year difference, p<0.001), which mirrors the Phase 3 PROACT 1 dosing regimen.
• The safety profile of rilparencel was consistent with previously reported study results and comparable to a kidney biopsy, with no rilparencel-related serious adverse events observed.
• Evidence of a dose response was suggested in Group 2, despite not achieving statistical significance.
• The FDA confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel if an acceptable surrogate endpoint, such as eGFR slope, is used.
• Current cash of $328 million is expected to fund operations into mid-2027, providing a solid financial runway.
• Rilparencel holds Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, indicating its potential to address unmet medical needs.

Negatives

• The improvement in annual eGFR slope in REGEN-007 Group 2 (50% improvement, 1.7 mL/min/1.73m2 per year difference) was not statistically significant (p=0.085).

Risks

• Disruptions to business or material harm to results/financial condition due to recent domestication to the United States.
• Inability to maintain the listing of Class A common stock on Nasdaq.
• Potential negative impact on the trading price of Class A common stock if excluded from various indices.
• Inability to implement business plans, forecasts, or realize additional opportunities, potentially affected by competition and the ability to grow profitably and retain key employees.
• Risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry.
• Risk that clinical trial results may not support regulatory approval.
• Risk that the FDA could require additional studies before approving drug candidates.
• Inability to raise future financing.
• Inability to obtain and maintain regulatory clearance or approval for products, and any related restrictions and limitations.
• Inability to identify, in-license, or acquire additional technology.
• Inability to compete with other companies in the biologics market and in the area of treatment of kidney diseases.
• Uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities.
• Interim results from clinical programs may not be indicative of future results.
• Impact of geo-political conflict on the business.

Future Outlook

ProKidney plans to submit the full REGEN-007 results to the American Society of Nephrology (ASN) 2025 Kidney Week. An FDA Type B meeting is scheduled for summer 2025 to confirm the eGFR slope as a surrogate endpoint for accelerated approval, with additional details expected mid-2025. The company will continue to focus on the enrollment of patients in its registrational Phase 3 PROACT 1 study and expects to provide an update on rilparencel's mechanism of action in the second half of 2025. Current cash is projected to fund operations into mid-2027.

Management Comments

• "We are very encouraged by the REGEN-007 topline results that demonstrated a robust improvement in eGFR slope following treatment with rilparencel in Group 1 as well as evidence of a dose response in Group 2."
• "These data bolster our confidence in the design of our ongoing Phase 3 PROACT 1 study given the similarity between the dosing regimen in REGEN-007 Group 1 and PROACT 1."
• "It is also worth noting that 15 of the 24 patients in Group 1 (63%) met key Phase 3 PROACT 1 inclusion criteria, and similar efficacy results were observed in this subgroup compared to the full Group 1 results."
• "We plan to submit the full results from REGEN-007 to ASNs 2025 Kidney Week as a late-breaking clinical trial and are excited to share more details at that time with investors and the medical community."
• "We also look forward to our upcoming FDA Type B meeting in the coming weeks to confirm our approach to eGFR slope as a surrogate endpoint for accelerated approval. This meeting represents an important step toward our goal of expediting rilparencels potential path to market in the U.S. where there remains a significant unmet clinical need in patients with advanced CKD and diabetes."

Industry Context

Chronic Kidney Disease (CKD) is a widespread and progressive condition affecting an estimated 37 million adults in the U.S., with diabetes being the primary cause. While existing treatments like ACE inhibitors, ARBs, and SGLT2 inhibitors aim to slow disease progression, there remains a substantial unmet need for therapies that can stabilize kidney function and delay or prevent the need for dialysis, particularly in patients with advanced CKD (Stage 3b/4 CKD and diabetes), a population estimated at 1 to 2 million in the U.S. Most recent landmark clinical trials in CKD have focused on earlier stages (Stage 2 and 3), and even with these therapies, patients often continue to experience kidney function decline. ProKidney's rilparencel, an autologous cellular therapy, represents a novel approach targeting this high-risk, underserved advanced CKD population, potentially offering a more significant impact on kidney function preservation than current standard-of-care options.

Comparison to Industry Standards

• Current standard of care for CKD, including ACE inhibitors, angiotensin receptor blockers, and SGLT2 inhibitors, aims to slow disease progression but does not prevent events in approximately 50-75% of people with diabetic kidney disease.
• For example, dapagliflozin (an SGLT2 inhibitor) demonstrated an approximate annual eGFR change of -2.86 mL/min/1.73m2 compared to standard of care at -3.79 mL/min/1.73m2, showing a slowing of decline but not stabilization or improvement.
• In contrast, ProKidney's rilparencel in REGEN-007 Group 1 showed a 78% improvement in annual eGFR slope, changing from a decline of -5.8 mL/min/1.73m2 to a decline of only -1.3 mL/min/1.73m2, representing a stabilization of kidney function.
• The document highlights that therapeutic options to delay dialysis in Stage 4 CKD are limited and that most recent landmark clinical trials primarily focus on Stage 2 and 3 CKD, positioning rilparencel as a potential breakthrough for a more advanced and underserved patient population.
• The observed stabilization of kidney function with rilparencel in Group 1, which mirrors the Phase 3 dosing, suggests a potentially superior outcome compared to the slowing of decline seen with current pharmaceutical standards of care in earlier CKD stages.

Stakeholder Impact

• Shareholders and Investors: The positive clinical trial results and regulatory progress are highly likely to increase investor confidence and potentially lead to a significant positive impact on the company's share price. The extended cash runway provides financial stability.
• Patients with Chronic Kidney Disease and Diabetes: Rilparencel offers a promising new therapeutic option to stabilize kidney function and potentially delay or prevent the need for dialysis, addressing a critical unmet medical need for those with advanced CKD.
• Medical Community: The detailed results, once presented at ASN Kidney Week, will provide valuable new data and insights into treating advanced CKD, potentially influencing future clinical practice and research.
• Employees: Positive clinical progress and a stable financial outlook contribute to job security and morale within the company.

Next Steps

• Submit full REGEN-007 results to the American Society of Nephrology (ASN) 2025 Kidney Week as a late-breaking clinical trial.
• Hold an FDA Type B meeting in summer 2025 to confirm the approach to using eGFR slope as the surrogate endpoint for accelerated approval.
• Provide an update on the accelerated approval pathway for PROACT 1 in mid-2025.
• Continue enrollment of patients in the registrational Phase 3 PROACT 1 study.
• Provide an update on rilparencel's mechanism of action in 2H 2025.

Key Dates

Recommendation

Keywords

Chronic Kidney Disease, CKD, Diabetes, Rilparencel, REGEN-007, PROACT 1, REGEN-006, Phase 2, Phase 3, Clinical Trial, eGFR, FDA, RMAT, Cellular Therapy, Biologics, Kidney Failure, End-Stage Kidney Disease, ESKD, Dialysis, Transplantation, PROK, ProKidney Corp.